Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

被引:93
|
作者
Younossi, Zobair M. [1 ,2 ]
Henry, Linda [3 ]
Bush, Haley [2 ]
Mishra, Alita [1 ]
机构
[1] Inova Fairfax Hosp, Ctr Liver Dis, Dept Med, 3300 Gallows Rd, Falls Church, VA 22042 USA
[2] Betty & Guy Beatty Ctr Integrated Res, Inova Hlth Syst, 3300 Gallows Rd, Falls Church, VA 22042 USA
[3] Ctr Outcomes Res Liver Dis, 2411 I St NW, Washington, DC 20037 USA
关键词
Prevalence; Risk factors; Mortality; Health-related quality of life; TERM-FOLLOW-UP; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; CARDIOVASCULAR-DISEASE; DIAGNOSTIC-ACCURACY; ETHNIC-DIFFERENCES; RACIAL-DIFFERENCES; FIBROSIS STAGE; NAFLD; PREVALENCE;
D O I
10.1016/j.cld.2017.08.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with an increasing global prevalence associated with tremendous clinical, economic, and health-related quality-of-life burden. Clinically, NAFLD is considered the liver manifestation of metabolic syndrome. However, diagnosing NAFLD presents significant challenges due to the limited noninvasive and accurate diagnostic tools available to not only accurately diagnose nonalcoholic steatohepatitis but also to stage hepatic fibrosis, the major predictor of long-term outcomes, including mortality.
引用
收藏
页码:1 / +
页数:11
相关论文
共 50 条